The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia
Abstract
BACKGROUND: In a preliminary dose-finding study, D-cycloserine, a partial agonist at the glycine modulatory site of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, improved negative symptoms and cognitive function when added to conventional neuroleptics at a dose of 50 mg/d. METHODS: Forty-seven patients with schizophrenia meeting criteria for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to their conventional neuroleptic for an 8-week, double-blind trial. Clinical assessments were performed at baseline and at weeks 1, 2, 4, 6, and 8. Serum concentrations of D-cycloserine, relevant amino acids, and homovanillic acid were assayed at baseline and at weeks 4 and 8. A cognitive battery was performed at baseline and at week 8. RESULTS: Thirty-nine patients completed the 8-week trial. Seven dropouts occurred in the D-cycloserine group and 1 in the placebo group. The mean reduction in negative symptoms with D-cycloserine (23%) was significantly greater than with placebo (7%) as calculated by slopes representing Scale for the Assessment of Negative Symptoms (SANS) total scores. Improvement of negative symptoms was predicted by low neuroleptic dose and low baseline SANS total score. No differences were found in performance on any cognitive test between groups or in changes in any other clinical measure. Clinical response did not correlate significantly with serum amino acid concentrations at baseline or with concentrations of D-cycloserine at weeks 4 and 8. CONCLUSION: These results support the hypothesis that agents acting at the glycine modulatory site of the NMDA receptor improve primary negative symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
(1976) · Medical Entomology and Zoology · Cited by 8,899
High-speed scanning in human memory
Sternberg, S. (1966) · Science · doi:10.1126/science.153.3736.652 · Cited by 3,576
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,422
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
The schedule for the deficit syndrome: An instrument for research in schizophrenia
Kirkpatrick, B., Buchanan, R. W., McKenny, P. D., Alphs, L. D., & Carpenter, W. T. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90153-4 · Cited by 808
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 1×
“R ECENT EFFORTS to direct pharmacological intervention at the N-methyl-Daspartate (NMDA) subtype of glutamate receptor have followed from evidence linking this receptor complex to schizophrenia.(1,2) For example, phencyclidine and ketamine, noncompetitive antagonists at the NMDA receptor complex, produce positive and…”
BackgroundSelf-citationVerbal Context and the Recall of Meaningful Material
Miller, G. A., & Selfridge, J. A. (1950) · The American Journal of Psychology · doi:10.2307/1418920 · Cited by 475
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.20 · Cited by 388
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Yamamoto, B., & Cooperman, M. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-07-04159.1994 · Cited by 203
Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90687-4 · Cited by 190
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Watson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., & Lanthorn, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90745-w · Cited by 172
Control of NMDA Receptor Activation by a Glycine Transporter Co-Expressed in Xenopus Oocytes
Supplisson, S., & Bergman, C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-12-04580.1997 · Cited by 167
Patient response and resource management: another view of clozapine treatment of schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.827 · Cited by 161
Henderson, G., Johnson, J. W., & Ascher, P. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018288 · Cited by 142
Role of Glycine in the N‐Methyl‐d‐Aspartate‐Mediated Neuronal Cytotoxicity
Patel, J. B., Zinkand, W. C., Thompson, C., Keith, R. A., & Salama, A. I. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02329.x · Cited by 115
Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients
van Berckel, B. N. M., Hijman, R., van der Linden, J. A., Westenberg, H. G. M., van Ree, J. M., & Kahn, R. S. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00311-3 · Cited by 109
Drug-induced extrapyramidal disorders.
Chase, T. N. (1972) · PubMed · Cited by 104
Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia
Rosse, R. B., Theut, S. K., Banay‐Schwartz, M., Leighton, M. P., Scarcella, E., Cohen, C. G., & Deutsch, S. I. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198910000-00006 · Cited by 101
Glycine Therapy of Schizophrenia
Waziri, R. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90093-5 · Cited by 100
Clozapine: is another view valid?
Meltzer, H. Y. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.821 · Cited by 95
New mechanisms of excitatory transmitter neurotoxicity.
Olney, J. W. (1994) · PubMed · Cited by 63
Banerjee, S., Zuck, L., Yablonsky-Alter, E., & Lidsky, T. I. (1995) · Neuroreport · doi:10.1097/00001756-199512150-00014 · Cited by 63
LAWLOR, B. A., & Davis, K. L. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90227-q · Cited by 63
Competitive antagonism of glycine at the N-methyl-d-aspartate (NMDA) receptor
Huettner, J. E. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90004-o · Cited by 61
Frontal brain volume and context effects in short-term recall in schizophrenia
Maher, B. A., Manschreck, T. C., Woods, B. T., Yurgelun-Todd, D. A., & Tsuang, M. T. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00203-f · Cited by 59
Fletcher, E. J., & MacDonald, J. F. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90148-b · Cited by 59
COSTA, J., Khaled, E., Sramek, J. J., Bunney, W. E., & Potkin, S. G. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199002000-00027 · Cited by 57
D-Cycloserine Adjuvant Therapy to Molindone in the Treatment of Schizophrenia
Rosse, R. B., Fay-McCarthy, M., Kendrick, K., Davis, E. R., & Deutsch, S. I. (1996) · Clinical Neuropharmacology · doi:10.1097/00002826-199619050-00008 · Cited by 54
Tardive dyskinesia and substrates of energy metabolism in CSF
GOFF, D. C., Tsai, G. E., Beal, M., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1730 · Cited by 52
Self-citationAbsorption, distribution, and excretion of cycloserine in man.
BARON, H., EPSTEIN, I. G., Mg, M., & Kg, N. (1955) · PubMed · Cited by 50
d-Cycloserine therapy of psychosis by symptom provocation
SIMEON, J. G., Fink, M., Itil, T. M., & Ponce, D. E. (1970) · Comprehensive Psychiatry · doi:10.1016/0010-440x(70)90207-5 · Cited by 43
Reduced primacy and related features in schizophrenia
Manschreck, T. C., Maher, B. A., Rosenthal, J. E., & Berner, J. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90051-r · Cited by 36
Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain
McCoy, L. A., & Richfield, E. K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12834-2 · Cited by 33
An autoradiographic study of the distribution of tritium-labeled cycloserine in mice.
Hanngren, H., HANSSON, E., & Ullberg, S. (1962) · PubMed · Cited by 12
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Self-citation
Metadata
- Authors
- Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-01-01
- Volume
- 56
- Issue
- 1
- Pages
- 21
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2078790185
- Cited by
- 436
- References
- 47
- FWCI
- 15.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.